An interventional study of STAR Intervention and Attention-Control in Osteoarthritis, Knee and Hypertension, sponsored by University of Pittsburgh. Completed at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by University of Pittsburgh · Not applicable, Interventional, and Treatment
The purpose of the Staying Active with Arthritis (STAR) research study is to determine if a 6-month program will improve leg exercise, fitness walking, and clinical outcomes (function, blood pressure, leg strength, pain, fatigue, and health-related quality of life) in older adults with osteoarthritis of the knee and high blood pressure.
Over 9 million Americans have symptomatic osteoarthritis (OA) of the knee, a chronic disease associated with frequent joint pain, functional limitations, and quadriceps weakness that intrude upon everyday life. At least half of those with OA of the knee are diagnosed with hypertension or high blood pressure (HBP), one of the most prevalent risk factors for cardiovascular disease. Many other individuals with OA of the knee unknowingly have HBP and remain untreated. Our own work and that of others suggest that persons with OA of the knee experience reductions in BP when they participate in a regular regimen of physical activity. Even small decreases in systolic and diastolic BP found with physical activity are clinically significant, e.g., a 2 mm Hg decrease reduces the risk of stroke by 14% - 17%, and the risk of coronary heart disease is reduced by 6% - 9%. Yet, only 15% of persons with OA and 47% with HBP engage in regular physical activity. The purpose of this study is to investigate how the individually delivered, home-based, 6-month modified Staying Active with Arthritis (STAR) intervention, guided by self-efficacy theory and modified to address comorbid HBP, affects lower extremity exercise (flexibility, strengthening, and balance), fitness walking, functional status, BP, quadriceps strength, pain, fatigue, and health-related quality of life (HRQoL) in a convenience sample of 224 adults age 50 years or older with OA of the knee and HBP. Using a randomized controlled, 2-group design, we (1) hypothesize that at the end of the 6-month intervention period and 6 months after the intervention period ends those who receive the modified STAR intervention will be more likely to perform lower extremity exercise, participate in fitness walking, show improvements in objective functional status, and demonstrate reductions in BP than those who receive attention-control. Secondarily, we will (2) evaluate the impact of the modified STAR intervention, compared to attention-control, on subjective functional status, quadriceps strength, pain, fatigue, and HRQoL at both time points; (3) explore the impact of the modified STAR intervention, compared to attention-control, on self-efficacy and outcome expectancy at both time points; (4) explore the relationship between self-efficacy and outcome expectancy; and (5) explore the extent to which self-efficacy and outcome expectancy mediate the relationship between the modified STAR intervention and performance of lower extremity exercise and participation in fitness walking. Data will be analyzed using repeated measures modeling.
4,398 studies on the registry are indexed under Osteoarthritis; 582 are open to participants now.
This study's enrollment of 182 is above the median of 70 across 3,440 interventional studies indexed under Osteoarthritis.
Browse Osteoarthritis studies →University of Pittsburgh is the lead sponsor of 1,385 studies on the registry; 167 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 4 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Staying Active with Arthritis Intervention
Behavioral: STAR Intervention
Senior Health Information Intervention
Behavioral: Attention-Control
The 24-week modified Staying Active with Arthritis (STAR) intervention, guided by self-efficacy theory and modified to address comorbid hypertension, consists of 6 weekly individual face-to-face exercise sessions by a licensed physical therapist, 9 biweekly telephone counseling sessions by a registered nurse to continue the use of self-efficacy strategies, and lower extremity exercise and fitness walking being carried out at home between sessions. There will be no contact with participants during weeks 7, 9, 11, 13, 15, 17, 19, 21, and 23. During the 6-month follow-up period, the participants will be contacted briefly by telephone by a registered nurse at weeks 30, 36, and 48 for a general check-up.
Attention-Control is a 24-week general health education program for older adults that consists of 6 weekly telephone sessions by a registered nurse followed by 9 biweekly telephone sessions by a registered nurse. There will be no contact with participants during weeks 7, 9, 11, 13, 15, 17, 19, 21, and 23. Topics include cancer screenings; immunizations; osteoporosis; low vision; hearing loss; talking with your primary care provider; eating healthy (two parts); sleep and aging; injury prevention (two parts: balance problems and falls); oral health; foot care; and mental health (depression). During the 6-month follow-up period, the participants will be contacted briefly by telephone by a registered nurse at weeks 30, 36, and 48 for a general check-up.
Performance of Lower Extremity Exercise at 25 Weeks
Measured by the electronic-diary in terms of the total volume of lower extremity exercise (i.e., the number of days the participant reports completing a lower extremity exercise session and the total number of lower extremity exercises per day performed \[repetitions x sets\] over a 7-day period).
Time frame: At the end of the 6-month intervention period (week 25)
Participation in Fitness Walking at 25 Weeks
Measured by the ActiGraph accelerometer in terms of mean daily activity minutes of none to very low, light, and moderate-to-vigorous activity counts summarized over a 7-day period.
Time frame: At the end of the 6-month intervention period (week 25)
Objective Functional Status by the 6-minute Walk at 25 Weeks
Measured by the 6-minute walk (yards) as part of the performance-based functional status assessment.
Time frame: At the end of the 6-month intervention period (week 25)
Objective Functional Status by the Short Physical Performance Battery at 25 Weeks
Measured by the Short Physical Performance Battery (total scale score) as part of the performance-based functional status assessment; subscale scores are summed for a total scale score; the scale score range is 0-13; higher scores are better.
Time frame: At the end of the 6-month intervention period (week 25)
Systolic Blood Pressure at 25 Weeks
Measured by the OMRON HEM-907XL automatic professional digital blood pressure monitor in mm Hg.
Time frame: At the end of the 6-month intervention period (week 25)
Diastolic Blood Pressure at 25 Weeks
Measured by the OMRON HEM-907XL automatic professional digital blood pressure monitor in mm Hg.
Time frame: At the end of the 6-month intervention period (week 25)
Performance of Lower Extremity Exercise at 52 Weeks
Measured by the electronic-diary in terms of the total volume of lower extremity exercise (i.e., the number of days the subject reports completing a lower extremity exercise session and the total number of lower extremity exercises per day performed \[repetitions x sets\] over a 7-day period).
Time frame: 6 months after the intervention period ends (week 52)
Participation in Fitness Walking at 52 Weeks
Measured by the ActiGraph accelerometer in terms of mean daily activity minutes of none to very low, light, and moderate-to-vigorous activity counts summarized over a 7-day period.
Time frame: 6 months after the intervention period ends (week 52)
Objective Functional Status by the 6-minute Walk at 52 Weeks
Measured by the 6-minute walk (yards) as part of the performance-based functional status assessment.
Time frame: 6 months after the intervention period ends (week 52)
Objective Functional Status by the Short Physical Performance Battery at 52 Weeks
Measured by the Short Physical Performance Battery (total scale score) as part of the performance-based functional status assessment; subscale scores are summed for a total scale score; the scale score range is 0-13; higher scores are better.
Time frame: 6 months after the intervention period ends (week 52)
Systolic Blood Pressure at 52 Weeks
Measured by the OMRON HEM-907XL automatic professional digital blood pressure monitor in mm Hg.
Time frame: 6 months after the intervention period ends (week 52)
Diastolic Blood Pressure at 52 Weeks
Measured by the OMRON HEM-907XL automatic professional digital blood pressure monitor in mm Hg.
Time frame: 6 months after the intervention period ends (week 52)
Subjective Functional Status at 25 Weeks
Measured by the Physical Function subscale of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index; the subscale score range is 0-68; lower scores are better.
Time frame: At the end of the 6-month intervention period (week 25)
Quadriceps Strength at 25 Weeks
Measured by the MicroFET2 hand-held dynamometer in terms of mean maximum pounds over two trials.
Time frame: At the end of the 6-month intervention period (week 25)
Pain by the Pain Subscale of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index at 25 Weeks
Measured by the Pain subscale of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index; the subscale score range is 0-20; lower scores are better.
Time frame: At the end of the 6-month intervention period (week 25)
Pain by the Bodily Pain Subscale of the Short Form-36v2 at 25 Weeks
Measured by the Bodily Pain subscale of the Short Form-36v2; the subscale score range is 0-100; higher scores are better.
Time frame: At the end of the 6-month intervention period (week 25)
Fatigue at 25 Weeks
Measured by the Brief Fatigue Inventory, which assesses fatigue severity; the scale score range is 0-10; lower scores are better.
Time frame: At the end of the 6-month intervention period (week 25)
Health-Related Quality of Life at 25 Weeks
Measured by the Short Form-36v2 in terms of the following: Mental Component: this summary scale is composed of eight subscale scores primarily derived from the mental health, role functioning-emotional, and social functioning scores; the scale score range is 0-100; higher scores are better Physical Component: this summary scale is composed of eight subscale scores primarily derived from the physical functioning, role functioning-physical, and bodily pain scores; the scale score range is 0-100; higher scores are better
Time frame: At the end of the 6-month intervention period (week 25)
Self-Efficacy at 25 Weeks
Measured by the Self-Efficacy Scale in terms of the following: Exercise Barriers Self-Efficacy subscale: the subscale score range is 0-100; higher scores are better Exercise Self-Efficacy subscale: the subscale score range is 0-100; higher scores are better
Time frame: At the end of the 6-month intervention period (week 25)
Arthritis Self-Efficacy at 25 Weeks
Measured by the Arthritis Self-Efficacy Scale in terms of the following: Pain subscale: the subscale score range is 10-100; higher scores are better Function subscale: the subscale score range is 10-100; higher scores are better Other Symptoms subscale: the subscale score range is 10-100; higher scores are better
Time frame: At the end of the 6-month intervention period (week 25)
Outcome Expectancy at 25 Weeks
Measured by the Perceived Therapeutic Efficacy Scale in terms of the following: Exercise and Arthritis: the scale score range is 0-100; higher scores are better Exercise and Hypertension: the scale score range is 0-100; higher scores are better
Time frame: At the end of the 6-month intervention period (week 25)
Subjective Functional Status at 52 Weeks
Measured by the Physical Function subscale of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index; the subscale score range is 0-68; lower scores are better.
Time frame: 6 months after the intervention period ends (week 52)
Quadriceps Strength at 52 Weeks
Measured by the MicroFET2 hand-held dynamometer in terms of mean maximum pounds over two trials.
Time frame: 6 months after the intervention period ends (week 52)
Pain by the Pain Subscale of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index at 52 Weeks
Measured by the Pain subscale of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index; the subscale score range is 0-20; lower scores are better.
Time frame: 6 months after the intervention period ends (week 52)
Pain by the Bodily Pain Subscale of the Short Form-36v2 at 52 Weeks
Measured by the Bodily Pain subscale of the Short Form-36v2; the subscale score range is 0-100; higher scores are better.
Time frame: 6 months after the intervention period ends (week 52)
Fatigue at 52 Weeks
Measured by the Brief Fatigue Inventory, which assesses fatigue severity; the scale score range is 0-10; lower scores are better.
Time frame: 6 months after the intervention period ends (week 52)
Health-Related Quality of Life at 52 Weeks
Measured by the Short Form-36v2 in terms of the following: Mental Component: this summary scale is composed of eight subscale scores primarily derived from the mental health, role functioning-emotional, and social functioning scores; the scale score range is 0-100; higher scores are better Physical Component: this summary scale is composed of eight subscale scores primarily derived from the physical functioning, role functioning-physical, and bodily pain scores; the scale score range is 0-100; higher scores are better
Time frame: 6 months after the intervention period ends (week 52)
Self-Efficacy at 52 Weeks
Measured by the Self-Efficacy Scale in terms of the following: Exercise Barriers Self-Efficacy subscale: the subscale score range is 0-100; higher scores are better Exercise Self-Efficacy subscale: the subscale score range is 0-100; higher scores are better
Time frame: 6 months after the intervention period ends (week 52)
Arthritis Self-Efficacy at 52 Weeks
Measured by the Arthritis Self-Efficacy Scale in terms of the following: Pain subscale: the subscale score range is 10-100; higher scores are better Function subscale: the subscale score range is 10-100; higher scores are better Other Symptoms subscale: the subscale score range is 10-100; higher scores are better
Time frame: 6 months after the intervention period ends (week 52)
Outcome Expectancy at 52 Weeks
Measured by the Perceived Therapeutic Efficacy Scale in terms of the following: Exercise and Arthritis: the scale score range is 0-100; higher scores are better Exercise and Hypertension: the scale score range is 0-100; higher scores are better
Time frame: 6 months after the intervention period ends (week 52)
| Milestone | STAR Intervention | Attention-Control |
|---|---|---|
| Started | 91 | 91 |
| Completed | 68 | 75 |
| Not completed | 23 | 16 |
| Withdrew: Lost to follow-up | 23 | 16 |
Measured by the electronic-diary in terms of the total volume of lower extremity exercise (i.e., the number of days the participant reports completing a lower extremity exercise session and the total number of lower extremity exercises per day performed \[repetitions x sets\] over a 7-day period).
| repetitions x sets/week | STAR Intervention | Attention-Control |
|---|---|---|
| Performance of Lower Extremity Exercise at 25 Weeks | 46.84 ± 4.59 | 1.90 ± 0.86 |
Measured by the ActiGraph accelerometer in terms of mean daily activity minutes of none to very low, light, and moderate-to-vigorous activity counts summarized over a 7-day period.
| minutes | STAR Intervention | Attention-Control |
|---|---|---|
| None to very low | 434.89 ± 11.69 | 409.98 ± 11.54 |
| Light | 314.07 ± 9.29 | 321.44 ± 9.18 |
| Moderate-to-vigorous | 40.53 ± 2.68 | 46.69 ± 3.93 |
Measured by the 6-minute walk (yards) as part of the performance-based functional status assessment.
| yards | STAR Intervention | Attention-Control |
|---|---|---|
| Objective Functional Status by the 6-minute Walk at 25 Weeks | 465.46 ± 18.82 | 483.02 ± 14.47 |
Measured by the Short Physical Performance Battery (total scale score) as part of the performance-based functional status assessment; subscale scores are summed for a total scale score; the scale score range is 0-13; higher scores are better.
| units on a scale | STAR Intervention | Attention-Control |
|---|---|---|
| Objective Functional Status by the Short Physical Performance Battery at 25 Weeks | 11.29 ± 0.22 | 10.86 ± 0.23 |
Measured by the OMRON HEM-907XL automatic professional digital blood pressure monitor in mm Hg.
| mm Hg | STAR Intervention | Attention-Control |
|---|---|---|
| Systolic Blood Pressure at 25 Weeks | 120.33 ± 1.74 | 123.07 ± 1.68 |
Measured by the OMRON HEM-907XL automatic professional digital blood pressure monitor in mm Hg.
| mm Hg | STAR Intervention | Attention-Control |
|---|---|---|
| Diastolic Blood Pressure at 25 Weeks | 71.74 ± 1.20 | 73.10 ± 1.16 |
Measured by the electronic-diary in terms of the total volume of lower extremity exercise (i.e., the number of days the subject reports completing a lower extremity exercise session and the total number of lower extremity exercises per day performed \[repetitions x sets\] over a 7-day period).
| repetitions x sets/week | STAR Intervention | Attention-Control |
|---|---|---|
| Performance of Lower Extremity Exercise at 52 Weeks | 42.06 ± 6.74 | 3.14 ± 1.22 |
Measured by the ActiGraph accelerometer in terms of mean daily activity minutes of none to very low, light, and moderate-to-vigorous activity counts summarized over a 7-day period.
| minutes | STAR Intervention | Attention-Control |
|---|---|---|
| None to very low | 426.71 ± 11.97 | 408.30 ± 11.70 |
| Light | 318.04 ± 9.50 | 321.01 ± 9.30 |
| Moderate-to-vigorous | 39.37 ± 2.74 | 47.97 ± 3.97 |
Measured by the 6-minute walk (yards) as part of the performance-based functional status assessment.
| yards | STAR Intervention | Attention-Control |
|---|---|---|
| Objective Functional Status by the 6-minute Walk at 52 Weeks | 480.29 ± 16.89 | 465.36 ± 19.26 |
Measured by the Short Physical Performance Battery (total scale score) as part of the performance-based functional status assessment; subscale scores are summed for a total scale score; the scale score range is 0-13; higher scores are better.
| units on a scale | STAR Intervention | Attention-Control |
|---|---|---|
| Objective Functional Status by the Short Physical Performance Battery at 52 Weeks | 11.20 ± 0.24 | 11.25 ± 0.19 |
Measured by the OMRON HEM-907XL automatic professional digital blood pressure monitor in mm Hg.
| mm Hg | STAR Intervention | Attention-Control |
|---|---|---|
| Systolic Blood Pressure at 52 Weeks | 122.54 ± 1.78 | 125.14 ± 1.71 |
Measured by the OMRON HEM-907XL automatic professional digital blood pressure monitor in mm Hg.
| mm Hg | STAR Intervention | Attention-Control |
|---|---|---|
| Diastolic Blood Pressure at 52 Weeks | 72.62 ± 1.22 | 74.06 ± 1.18 |
Measured by the Physical Function subscale of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index; the subscale score range is 0-68; lower scores are better.
| units on a scale | STAR Intervention | Attention-Control |
|---|---|---|
| Subjective Functional Status at 25 Weeks | 16.68 ± 1.44 | 18.30 ± 1.42 |
Measured by the MicroFET2 hand-held dynamometer in terms of mean maximum pounds over two trials.
| pounds | STAR Intervention | Attention-Control |
|---|---|---|
| Quadriceps Strength at 25 Weeks | 43.21 ± 1.75 | 41.88 ± 1.71 |
Measured by the Pain subscale of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index; the subscale score range is 0-20; lower scores are better.
| units on a scale | STAR Intervention | Attention-Control |
|---|---|---|
| Pain by the Pain Subscale of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index at 25 Weeks | 4.25 ± 0.39 | 4.54 ± 0.38 |
Measured by the Bodily Pain subscale of the Short Form-36v2; the subscale score range is 0-100; higher scores are better.
| units on a scale | STAR Intervention | Attention-Control |
|---|---|---|
| Pain by the Bodily Pain Subscale of the Short Form-36v2 at 25 Weeks | 59.65 ± 2.32 | 58.13 ± 2.26 |
Measured by the Brief Fatigue Inventory, which assesses fatigue severity; the scale score range is 0-10; lower scores are better.
| units on a scale | STAR Intervention | Attention-Control |
|---|---|---|
| Fatigue at 25 Weeks | 2.49 ± 0.27 | 2.76 ± 0.25 |
Measured by the Short Form-36v2 in terms of the following: Mental Component: this summary scale is composed of eight subscale scores primarily derived from the mental health, role functioning-emotional, and social functioning scores; the scale score range is 0-100; higher scores are better Physical Component: this summary scale is composed of eight subscale scores primarily derived from the physical functioning, role functioning-physical, and bodily pain scores; the scale score range is 0-100; higher scores are better
| units on a scale | STAR Intervention | Attention-Control |
|---|---|---|
| Short Form-36v2 Mental Component | 53.92 ± 1.11 | 52.30 ± 1.20 |
| Short Form-36v2 Physical Component | 43.10 ± 0.97 | 43.07 ± 0.95 |
Measured by the Self-Efficacy Scale in terms of the following: Exercise Barriers Self-Efficacy subscale: the subscale score range is 0-100; higher scores are better Exercise Self-Efficacy subscale: the subscale score range is 0-100; higher scores are better
| units on a scale | STAR Intervention | Attention-Control |
|---|---|---|
| Exercise Barriers Self-Efficacy | 59.81 ± 2.77 | 58.37 ± 2.69 |
| Exercise Self-Efficacy | 67.43 ± 3.44 | 60.20 ± 3.35 |
Measured by the Arthritis Self-Efficacy Scale in terms of the following: Pain subscale: the subscale score range is 10-100; higher scores are better Function subscale: the subscale score range is 10-100; higher scores are better Other Symptoms subscale: the subscale score range is 10-100; higher scores are better
| units on a scale | STAR Intervention | Attention-Control |
|---|---|---|
| Arthritis Self Efficacy Pain | 75.58 ± 1.97 | 67.38 ± 2.13 |
| Arthritis Self-Efficacy Function | 85.74 ± 1.79 | 85.90 ± 1.67 |
| Arthritis Self-Efficacy Other Symptoms | 78.88 ± 1.99 | 77.66 ± 1.95 |
Measured by the Perceived Therapeutic Efficacy Scale in terms of the following: Exercise and Arthritis: the scale score range is 0-100; higher scores are better Exercise and Hypertension: the scale score range is 0-100; higher scores are better
| units on a scale | STAR Intervention | Attention-Control |
|---|---|---|
| Perceived Therapeutic Efficacy Arthritis | 72.79 ± 2.41 | 59.67 ± 2.91 |
| Perceived Therapeutic Efficacy Hypertension | 77.14 ± 2.48 | 69.62 ± 2.42 |
Measured by the Physical Function subscale of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index; the subscale score range is 0-68; lower scores are better.
| units on a scale | STAR Intervention | Attention-Control |
|---|---|---|
| Subjective Functional Status at 52 Weeks | 17.02 ± 1.49 | 17.51 ± 1.44 |
Measured by the MicroFET2 hand-held dynamometer in terms of mean maximum pounds over two trials.
| pounds | STAR Intervention | Attention-Control |
|---|---|---|
| Quadriceps Strength at 52 Weeks | 43.66 ± 1.77 | 43.33 ± 1.73 |
Measured by the Pain subscale of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index; the subscale score range is 0-20; lower scores are better.
| units on a scale | STAR Intervention | Attention-Control |
|---|---|---|
| Pain by the Pain Subscale of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index at 52 Weeks | 4.09 ± 0.41 | 4.72 ± 0.39 |
Measured by the Bodily Pain subscale of the Short Form-36v2; the subscale score range is 0-100; higher scores are better.
| units on a scale | STAR Intervention | Attention-Control |
|---|---|---|
| Pain by the Bodily Pain Subscale of the Short Form-36v2 at 52 Weeks | 59.73 ± 2.36 | 59.70 ± 2.28 |
Measured by the Brief Fatigue Inventory, which assesses fatigue severity; the scale score range is 0-10; lower scores are better.
| units on a scale | STAR Intervention | Attention-Control |
|---|---|---|
| Fatigue at 52 Weeks | 2.97 ± 0.28 | 2.94 ± 0.25 |
Measured by the Short Form-36v2 in terms of the following: Mental Component: this summary scale is composed of eight subscale scores primarily derived from the mental health, role functioning-emotional, and social functioning scores; the scale score range is 0-100; higher scores are better Physical Component: this summary scale is composed of eight subscale scores primarily derived from the physical functioning, role functioning-physical, and bodily pain scores; the scale score range is 0-100; higher scores are better
| units on a scale | STAR Intervention | Attention-Control |
|---|---|---|
| Short Form-36v2 Mental Component | 53.18 ± 1.12 | 51.81 ± 1.21 |
| Short Form-36v2 Physical Component | 42.10 ± 1.18 | 42.47 ± 1.15 |
Measured by the Self-Efficacy Scale in terms of the following: Exercise Barriers Self-Efficacy subscale: the subscale score range is 0-100; higher scores are better Exercise Self-Efficacy subscale: the subscale score range is 0-100; higher scores are better
| units on a scale | STAR Intervention | Attention-Control |
|---|---|---|
| Exercise Barriers Self-Efficacy | 53.30 ± 2.83 | 53.05 ± 2.73 |
| Exercise Self-Efficacy | 55.49 ± 3.56 | 51.00 ± 3.43 |
Measured by the Arthritis Self-Efficacy Scale in terms of the following: Pain subscale: the subscale score range is 10-100; higher scores are better Function subscale: the subscale score range is 10-100; higher scores are better Other Symptoms subscale: the subscale score range is 10-100; higher scores are better
| units on a scale | STAR Intervention | Attention-Control |
|---|---|---|
| Arthritis Self-Efficacy Pain | 73.15 ± 2.06 | 69.44 ± 2.19 |
| Arthritis Self-Efficacy Function | 85.38 ± 1.82 | 87.75 ± 1.69 |
| Arthritis Self-Efficacy Other Symptoms | 75.92 ± 2.03 | 75.23 ± 1.96 |
Measured by the Perceived Therapeutic Efficacy Scale in terms of the following: Exercise and Arthritis: the scale score range is 0-100; higher scores are better Exercise and Hypertension: the scale score range is 0-100; higher scores are better
| units on a scale | STAR Intervention | Attention-Control |
|---|---|---|
| Perceived Therapeutic Efficacy Arthritis | 67.09 ± 2.83 | 55.86 ± 3.07 |
| Perceived Therapeutic Efficacy Hypertension | 73.40 ± 2.53 | 67.93 ± 2.44 |
Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| STAR Intervention | — | 0/91 (0%) | 0/91 (0%) |
| Attention-Control | — | 0/91 (0%) | 0/91 (0%) |
| Age, Continuous(years) | STAR Intervention | Attention-Control | Total |
|---|---|---|---|
| Mean | 64.47 ± 8.46 | 64.96 ± 7.76 | 64.71 ± 8.10 |
| Sex: Female, Male(Participants) | STAR Intervention | Attention-Control | Total |
|---|---|---|---|
| Female | 67 | 66 | 133 |
| Male | 24 | 25 | 49 |
| Ethnicity (NIH/OMB)(Participants) | STAR Intervention | Attention-Control | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 3 | 6 |
| Not Hispanic or Latino | 88 | 88 | 176 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | STAR Intervention | Attention-Control | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 17 | 15 | 32 |
| White | 66 | 66 | 132 |
| More than one race | 5 | 9 | 14 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | STAR Intervention | Attention-Control | Total |
|---|---|---|---|
| United States | 91 | 91 | 182 |
| Body mass index(kg/m²) | STAR Intervention | Attention-Control | Total |
|---|---|---|---|
| Mean | 34.50 ± 7.48 | 33.64 ± 6.43 | 34.07 ± 6.97 |
| Number of comorbidities(comorbidities) | STAR Intervention | Attention-Control | Total |
|---|---|---|---|
| Mean | 6.8 ± 2.9 | 6.5 ± 2.7 | 6.6 ± 2.8 |
| Marital status(participants) | STAR Intervention | Attention-Control | Total |
|---|---|---|---|
| Married | 38 | 46 | 84 |
| Not married | 53 | 45 | 98 |
44 further baseline measures are reported on the registry.
Plan to share: No
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Pittsburgh